Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Background/Aims Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment respon...
Main Authors: | Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2016-09-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2016-0047.pdf |
Similar Items
-
Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients
by: Yuan-wang Qiu, et al.
Published: (2016-02-01) -
Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
by: Jaemin Lee, et al.
Published: (2016-09-01) -
Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01) -
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
by: David Sooik Kim, et al.
Published: (2019-09-01) -
Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
by: Si-Hai Zhao, et al.